TOYOPEARL® MX-Trp-650M Mixed-Mode Resin
TOYOPEARL MX-Trp-650M is a new multimodal cation exchange resin with unique selectivity and high recovery. It provides high protein binding capacities and tolerates high conductivity feedstocks.
TOYOPEARL® MX-Trp-650M is a new multimodal cation exchange resin with unique selectivity and high recovery. It provides high protein binding capacities and tolerates high conductivity feedstocks.
TOYOPEARL® MX-Trp-650M is based on a rigid methacrylic polymer matrix, which provides excellent pressure/flow properties and allows high flow rates at large scale. Its ligand, the amino acid tryptophan, provides ionic and hydrophobic interactions. TOYOPEARL® MX-Trp-650M combines the selectivity options of mixed-mode chromatography with the binding capacity of modern ion exchange resins. This new mixed-mode resin is well-suited for intermediate and polishing steps, such as aggregate removal in antibody purification, and for the purification of targets that are difficult to purify using common purification platforms.
For more information visit the website
www.tosohbioscience.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
